MedPath

Observational study monitoring the effects of oral cabergoline on avoidance of symptoms of Ovarian Hyperstimulation Syndrome (OHSS) in patients at risk of ovarian hyperstimulation syndrome when undergoing an In-Vitro Fertilisation (IVF) cycle

Not Applicable
Completed
Conditions
Ovarian hyperstimulation syndrome (OHSS)
Reproductive Health and Childbirth - Fertility including in vitro fertilisation
Registration Number
ACTRN12609000222246
Lead Sponsor
Fertility Specialists of Western Australia
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
100
Inclusion Criteria

Patients whose oestradiol level is >15,000 pmol/l, or more than 20 follicles on ultrasound examination prior to the day of HCG trigger

Exclusion Criteria

Patients with a significant concurrent medical illness or a contraindication to the administration of cabergoline.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath